Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 2/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4880724 | 0.86 | KDM4E (0.44) | KDM4EALDH1A1KMT2AELANENOTUM | |
| SCHEMBL4879872 | 0.83 | KDM4E (0.60) | DYRK1AKDM4EALDH1A1KMT2AELANE | |
| SCHEMBL27684341 | 0.82 | NPSR1 (0.55) | KDM4EALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL19826844 | 0.78 | LRRK2 (0.48) | DYRK1AKDM4EALDH1A1HSD17B10MEN1 | |
| SCHEMBL926696 | 0.77 | GPBAR1 (0.57) | KDM4EALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL30686330 | 0.77 | GPBAR1 (0.57) | KDM4EALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL4881013 | 0.76 | SMN1; SMN2 (0.67) | ALDH1A1HSD17B10KMT2ASMN1; SMN2MALT1 | |
| SCHEMBL20406252 | 0.75 | CYP1A2 (0.53) | KDM4EALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL27703385 | 0.75 | CYP1A2 (0.49) | KDM4EALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL26107713 | 0.74 | NOTUM (0.59) | KDM4EALDH1A1HSD17B10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080153850-A1 | Adamantyl Derivates as P2x7 Receptor Antagonists | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| EP-1786786-A1 | ADAMANTYL DERIVATES AS P2X7 RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006025783-A1 | ADAMANTYL DERIVATES AS P2X7 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153850-A1 | Adamantyl Derivates as P2x7 Receptor Antagonists | ADORA1, P2RX1, P2RY1 | DYRK1A 1307/4885KDM4E 4115/4885ALDH1A1 744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.